EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Homologous Recombination Repair Gene Mutations in Prostate Cancer: Prevalence and Clinical Value

Yu Fan, Zhenhua Liu, Yuke Chen, Zhisong He iD

Advances in Therapy · 2024-06 · 41 (6) · 2196-2216

DOI: 10.1007/s12325-024-02844-7 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advances in Therapy, online erschienen am 20.05.2024. Verfasst von Yu Fan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing, China. Hauptthemen laut MEDLINE: Mutation, Recombinational DNA Repair, Prostatic Neoplasms, Castration-Resistant, Poly(ADP-ribose) Polymerase Inhibitors. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 121 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: MSD China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite advances in our understanding of the molecular landscape of prostate cancer and the development of novel biomarker-driven therapies, the prognosis of patients with metastatic prostate cancer that is resistant to conventional hormonal therapy remains poor. Data suggest that a significant proportion of patients with metastatic castration-resistant prostate cancer (mCRPC) have mutations in homologous recombination repair (HRR) genes and may benefit from poly(ADP-ribose) polymerase (PARP) inhibitors. However, the adoption of HRR gene mutation testing in prostate cancer remains low, meaning there is a missed opportunity to identify patients who may benefit from targeted therapy with PARP inhibition, with or without novel hormonal agents. Here, we review the current knowledge regarding the clinical significance of HRR gene mutations in prostate cancer and discuss the efficacy of PARP inhibition in patients with mCRPC. This comprehensive overview aims to increase the clinical implementation of HRR gene mutation testing and inform future efforts in personalized treatment of prostate cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MutationRecombinational DNA RepairProstatic Neoplasms, Castration-ResistantPoly(ADP-ribose) Polymerase InhibitorsHumansMaleProstatic NeoplasmsPrevalencePrognosis

Stichwörter der Autor:innen

Homologous recombination repairPARP inhibitorsProstate cancer

Substanzen

Poly(ADP-ribose) Polymerase Inhibitors

Autor:innen und Institutionen

  • Department of Urology, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing, China.
  • Global Medical Affairs, MSD China, Shanghai, China.
  • Department of Urology, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing, China. wyj7074@sohu.com.

ORCID-Profile: Zhisong He

Förderung

  • MSD China

Zitieren

APA

Fan, Y., Liu, Z., Chen, Y., & He, Z. (2024). Homologous Recombination Repair Gene Mutations in Prostate Cancer: Prevalence and Clinical Value. Advances in Therapy, 41(6), 2196-2216. https://doi.org/10.1007/s12325-024-02844-7

Vancouver

Fan Y, Liu Z, Chen Y, He Z. Homologous Recombination Repair Gene Mutations in Prostate Cancer: Prevalence and Clinical Value. Advances in Therapy. 2024;41(6):2196-2216. doi:10.1007/s12325-024-02844-7

BibTeX
@article{Fan2024,
  author = {Fan, Yu and Liu, Zhenhua and Chen, Yuke and He, Zhisong},
  title = {Homologous Recombination Repair Gene Mutations in Prostate Cancer: Prevalence and Clinical Value},
  journal = {Advances in Therapy},
  year = {2024},
  volume = {41},
  number = {6},
  pages = {2196--2216},
  doi = {10.1007/s12325-024-02844-7}
}
Kostenlos starten →